header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

PAEDIATRIC ACUTE HAEMATOGENOUS OSTEOMYELITIS – A 9 YEAR REVIEW IN AUCKLAND



Abstract

Acute haematogenous osteomyelitis in children is relatively uncommon but delay in diagnosis and inadequate treatment can result in significant morbidity. Most recently evidence has suggested conservative treatment with adequate antibiotic therapy should be the mainstay, with provision for surgical intervention in those who fail to respond to conservative management. The outcome of primary management has been evaluated in this review.

Retrospective analysis of an osteomyelitis database was conducted on individuals presenting to Auckland’s Starship and Middlemore Hospital with an ICD-10 diagnosis of Osteomyelitis between January the 1st 1999 and December the 31st 2008.

813 children fulfilled the criteria for inclusion into this review. The annual incidence of acute haematogenous osteomyelitis in the paediatric population in Auckland over this period was approximately 1:4,000. 64% were male and 36% were female. The majority were New Zealand European (35%), with the other significant ethnic groups represented being New Zealand Maori (22%), and Pacific Island (30%). 23% of patients were aged less than three. 51% of patients were between three and ten, and 26% older than ten. Only 32% had an elevated white cell count on admission. A responsible pathogen was isolated in 50% with the most common being Staphylococcus aureus, which was isolated in 77% of this group. Diagnosis was made radiologically in 66%, clinically in 27%, and surgically after exploration in 7%. The most common site of osteomyelitis was the femur in 254 individuals, followed by the tibia in 198 individuals. 49 had multi-focal involvement. Flucloxacillin was the most common antibiotic used, with 510 individuals being administered flucloxacillin at one point in time during their management. The average length of treatment was 43.7 days, which included intravenous therapy of 22.3 days, and oral therapy of 21.4 days. 60% had a range of duration of therapy from greater than three weeks through to six weeks. 44% required surgical intervention. The relapse rate was 6.8%. The average duration till relapse was 5.8 months. Only 1.7% of the total population went on to develop chronic osteomyelitis.

The incidence of paediatric acute haematogenous osteomyelitis in this population appears to be relatively high. The average length of treatment was longer than that now reported to be successful for eradication. This could possibly be a factor in the relatively low rate of relapse and low subsequent rate of chronic osteomyelitis.

Correspondence should be addressed to: Associate Professor N. Susan Stott, Orthopaedic Department, Starship Children’s Hospital, Private Bag 92024, Auckland, New Zealand.